Franck and colleagues demonstrated that MSCs inhibit NET-MPO even after the release of NETs from activated neutrophils, indicating that MSCs may have therapeutic potential to treat autoimmune diseases or inflammatory conditions that are driven by the catalytic activity of MPO [37,41]. This evidence concerns the gene MPO and autoimmune disease.